TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has launched an underwritten initial public offering of 5,000,000 shares of its common stock at an initial public offering price expected to be between $14.00 and $16.00 per share. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. All of the shares to be sold in the proposed offering will be offered by TCR2 . TCR2 has applied to list the shares on the Nasdaq Global Market under the symbol “TCRR”.
Jefferies, SVB Leerink and BMO Capital Markets are acting as joint book running managers for the offering. Wedbush PacGrow and China Renaissance are acting as co-managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
TCR2 has developed a platform, “TruC”, designed to develop immune cells that incorporate the best features of CAR-T and TCR-T cell therapies and overcome their limitations. The TRuC platform is a novel T cell therapy platform, which uses the complete TCR complex without the need for HLA matching.
The company currently has five candidates in development. TC-210 is the most advanced in terms of development stage and targets mesothelin-positive solid tumors.